含不同H5血凝素同源与异源抗原匹配疫苗对鸡抵御2014年美国H5N8与H5N2分支2.3.4.4高致病性禽流感病毒提供不同保护
研究评估了与2.3.4.4病毒遗传相关性85%–100%的多种现有H5疫苗,鸡单剂接种灭活全病毒H5疫苗或表达H5血凝素基因的重组禽痘病毒、火鸡疱疹病毒载体疫苗后,分别以美国野鸟H5N8或H5N2分支2.3.4.4分离株攻击;多数灭活H5疫苗对H5N8或H5N2攻击提供100%保护,重组活载体疫苗仅提供40%–70%的部分保护。
要点
- 多数灭活H5疫苗对H5N8或H5N2攻击提供100%保护,重组活载体疫苗仅提供40%–70%部分保护。
- 灭活疫苗组排毒鸡数一般较少且病毒滴度较低,重组疫苗组排毒鸡数较多且滴度较高。
- 异源疫苗组攻击前用HPAI攻击病毒作抗原测得的抗体滴度通常较低(≤2 log2),但多数鸡仍存活。
核心结论
- 现有疫苗单次免疫策略可能无法为家禽抵御2.3.4.4高致病性禽流感病毒提供足够保护。
- 将H5血凝素更新为与暴发病毒遗传更接近和/或采用初免-加强策略,可能是获得最佳保护所必需的。
研究设计与样本
- 研究评估了与2.3.4.4高致病性禽流感病毒遗传相关性85%–100%的多种现有H5疫苗或疫苗种子株在禽类中的保护效果。
- 鸡单剂接种灭活全H5禽流感疫苗,或表达H5禽流感血凝素基因的重组禽痘病毒载体疫苗或火鸡疱疹病毒载体疫苗,随后以美国野鸟H5N8(A/gyrfalcon/Washington/40188-6/2014)或H5N2(A/northern pintail/Washington/40964/2014)分支2.3.4.4分离株攻击。
主要发现
- 多数灭活H5疫苗对H5N8或H5N2攻击的致死效应提供100%保护。
- 重组活载体疫苗仅提供部分保护,范围为40%–70%。
- 灭活疫苗组排毒鸡数一般较少且病毒滴度较低,重组疫苗组排毒鸡数较多且滴度较高。
- 异源疫苗组攻击前用HPAI攻击病毒作抗原测得的抗体滴度通常较低(≤2 log2),但多数鸡仍存活。
局限性
- 作者指出这些研究提示现有疫苗单次免疫策略可能无法为家禽抵御2.3.4.4高致病性禽流感病毒提供足够保护。
- 作者提出将H5血凝素更新为与暴发病毒遗传更接近和/或采用初免-加强策略可能是获得最佳保护所必需的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
From December 2014 to June 2015, a novel H5 Eurasian A/goose/Guangdong (Gs/GD) lineage clade 2.3.4.4 high pathogenicity avian influenza (HPAI) virus caused the largest animal health emergency in US history resulting in mortality or culling of greater than 48 million poultry. The outbreak renewed interest in developing intervention strategies, including vaccines, for these newly emergent HPAI viruses. In these studies, several existing H5 vaccines or vaccine seed strains with varying genetic relatedness (85-100%) to the 2.3.4.4 HPAI viruses were evaluated for protection in poultry. Chickens received a single dose of either an inactivated whole H5 AI vaccine, or a recombinant fowl poxvirus or turkey herpesvirus-vectored vaccines with H5 AI hemagglutinin gene inserts followed by challenge with either a U.S. wild bird H5N8 (A/gyrfalcon/Washington/40188-6/2014) or H5N2 (A/northern pintail/Washington/40964/2014) clade 2.3.4.4 isolate. Results indicate that most inactivated H5 vaccines provided 100% protection from lethal effects of H5N8 or H5N2 challenge. In contrast, the recombinant live vectored vaccines only provided partial protection which ranged from 40 to 70%. Inactivated vaccine groups, in general, had lower number of birds shedding virus and at lower virus titers then the recombinant vaccine groups. Interestingly, prechallenge antibody titers using the HPAI challenge viruses as antigen in heterologous vaccine groups were typically low (≤2 log2), yet the majority of these birds survived challenge. Taken together, these studies suggest that existing vaccines when used in a single immunization strategy may not provide adequate protection in poultry against the 2.3.4.4 HPAI viruses. Updating the H5 hemagglutinin to be genetically closer to the outbreak virus and/or using a prime-boost strategy may be necessary for optimal protection.
引用
- Kapczynski DR, Pantin-Jackwood MJ, Spackman E, et al. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses. Vaccine. 2017. PMID: 28456525. doi:10.1016/j.vaccine.2017.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。